GoldenGolden
Advanced Search

TOT Biopharm

A clinical-stage biopharmaceutical company in Jiangsu, China that focuses on developing and commercializing oncology drugs and therapies.

TOT BIOPHARM is a clinical-stage biopharmaceutical company in Jiangsu, China that focuses on developing and commercializing oncology drugs and therapies. Founded 2009 in Suzhou, Jiangsu, China, focuses on developing oncology treatments. Their biomedical pilot research and commercial production use a disposable bioreactor system to strengthen production safety and reduce production costs. The company has independently developed a new cell expansion technology, namely "perfusion-batch mixed culture technology", which is suitable for the commercial production of monoclonal antibodies. This technology can be used for seed expansion in a 25-liter bioreactor without the use of The 50-liter, 200-liter and 500-liter bioreactors are directly expanded to 2,000-liter bioreactors, thereby saving capital expenditure, facility space, production costs and production time.

TOT BIOPHARM has established three integrated technology platforms, including: The Therapeutic Monoclonal Antibody and Antibody Drugs Conjugates(ADC) Technology Platform, The Gene Engineering Based Therapeutics Technology Platform and The Innovative Drug Delivery Technology Platform. Therapeutic monoclonal antibody and ADC drug technology platform integrated the company's R&D and production capacity, enabling the company to develop a series of antibody drugs and ADC. The therapeutic technology platform based on gene engineering integrates anti-tumor immunotherapy, gene therapy and viral therapy, and carries out research and development and production of recombinant virus vector systems for tumor targets. The delivery technology platform includes advanced targeted liposome drug delivery systems that have key embedding technologies for both hydrophobic and hydrophilic compounds to avoid the breakdown of the embedded composition and to release the embedded composition at the intended target site.

Timeline

August 2018
TOT Biopharm raises a $102,000,000 series B round from Cathay Capital, Center Laboratories Group, Chengwei Capital, China Universal, GP Group, Vivo Capital and Yuanta Financial Holdings Group.
2009
Founded

Funding rounds

People

Name
Role
LinkedIn

Rongjin Lin

Chairman

Further reading

Title
Author
Link
Type
Date

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.